Aerie Pharmaceuticals Inc(AERI) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, dry eye, retinal diseases, and other eye diseases. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension. The company is also developing AVX-012, a clinical-stage dry eye product candidate; and AR-1105 and AR-13503 sustained-release implants for treating retinal diseases. Aerie Pharmaceuticals, Inc. has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.

Current Price

$17.51

RSI

59.460

Beta:

0.724765

February 26, 2021
224.8M
21.8M

-27.209 %
61.637 %
25.797 %
5.322 %

$85,138,000
$72,888,000
$27,851,000
$-1,501,000
$-2,537,000
$0
16.807 %
161.707 %
105.389 %
69.021 %
0.000 %

$-177,856,000
$-199,671,000
$-232,566,000
$-146,863,000
$-98,866,000
$-74,224,000
12.266 %
16.475 %
-36.851 %
-32.681 %
-24.925 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.